Stake logo

GHRS

GH RESEARCH PLC

About GHRS

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, it has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). GH002 is its 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. GH003 is its 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Buy US stocks in Australia starting with GHRS. Open an account and start investing today!

Market Capitalisation

$530.61M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

0

High today

$10.28

Low today

$9.28

Open price

$0.00

52-week high

$20.34

52-week low

$8.46


GHRS FAQs

One share of GH RESEARCH PLC is valued at $10.28.

The ticker symbol for GH RESEARCH PLC is GHRS.

To buy GHRS stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in GHRS

As of 07/02/2023 GH RESEARCH PLC has a market cap of $531M.

The GH RESEARCH PLC 52-week high stock price is $20.34.

The GH RESEARCH PLC 52-week low stock price is $8.46.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.